It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARWR’s FA Score shows that 1 FA rating(s) are green whileUCBJY’s FA Score has 3 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARWR’s TA Score shows that 3 TA indicator(s) are bullish while UCBJY’s TA Score has 6 bullish TA indicator(s).
ARWR (@Biotechnology) experienced а -1.21% price change this week, while UCBJY (@Biotechnology) price change was +10.07% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +13.39%. For the same industry, the average monthly price growth was +3.80%, and the average quarterly price growth was +9.29%.
ARWR is expected to report earnings on Feb 05, 2025.
UCBJY is expected to report earnings on Feb 27, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
ARWR | UCBJY | ARWR / UCBJY | |
Capitalization | 2.34B | 35.8B | 7% |
EBITDA | -508.26M | 1.12B | -45% |
Gain YTD | -38.595 | 123.624 | -31% |
P/E Ratio | N/A | 150.89 | - |
Revenue | 19.6M | 5.45B | 0% |
Total Cash | 434M | 689M | 63% |
Total Debt | 118M | 3.04B | 4% |
ARWR | UCBJY | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 16 | |
SMR RATING 1..100 | 98 | 95 | |
PRICE GROWTH RATING 1..100 | 83 | 39 | |
P/E GROWTH RATING 1..100 | 2 | 8 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
UCBJY's Valuation (2) in the null industry is significantly better than the same rating for ARWR (95) in the Biotechnology industry. This means that UCBJY’s stock grew significantly faster than ARWR’s over the last 12 months.
UCBJY's Profit vs Risk Rating (16) in the null industry is significantly better than the same rating for ARWR (100) in the Biotechnology industry. This means that UCBJY’s stock grew significantly faster than ARWR’s over the last 12 months.
UCBJY's SMR Rating (95) in the null industry is in the same range as ARWR (98) in the Biotechnology industry. This means that UCBJY’s stock grew similarly to ARWR’s over the last 12 months.
UCBJY's Price Growth Rating (39) in the null industry is somewhat better than the same rating for ARWR (83) in the Biotechnology industry. This means that UCBJY’s stock grew somewhat faster than ARWR’s over the last 12 months.
ARWR's P/E Growth Rating (2) in the Biotechnology industry is in the same range as UCBJY (8) in the null industry. This means that ARWR’s stock grew similarly to UCBJY’s over the last 12 months.
ARWR | UCBJY | |
---|---|---|
RSI ODDS (%) | 2 days ago80% | 2 days ago58% |
Stochastic ODDS (%) | 2 days ago74% | 2 days ago55% |
Momentum ODDS (%) | 2 days ago84% | 2 days ago51% |
MACD ODDS (%) | 2 days ago76% | 2 days ago50% |
TrendWeek ODDS (%) | 2 days ago84% | 2 days ago68% |
TrendMonth ODDS (%) | 2 days ago84% | 2 days ago74% |
Advances ODDS (%) | 2 days ago78% | 2 days ago65% |
Declines ODDS (%) | 12 days ago83% | 8 days ago54% |
BollingerBands ODDS (%) | 2 days ago90% | 2 days ago39% |
Aroon ODDS (%) | 2 days ago68% | 2 days ago70% |
A.I.dvisor tells us that UCBJY and GBIO have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that UCBJY and GBIO's prices will move in lockstep.
Ticker / NAME | Correlation To UCBJY | 1D Price Change % | ||
---|---|---|---|---|
UCBJY | 100% | +2.89% | ||
GBIO - UCBJY | 28% Poorly correlated | +2.19% | ||
VANI - UCBJY | 26% Poorly correlated | +2.24% | ||
ABOS - UCBJY | 24% Poorly correlated | -0.42% | ||
TNYA - UCBJY | 23% Poorly correlated | +24.37% | ||
ARWR - UCBJY | 23% Poorly correlated | +1.35% | ||
More |